The targeted inhibition of antiapoptotic factors in tumour cells may provide a rational approach towards the development of novel anticancer therapies. Using human papillomavirus (HPV)-transformed cells as a model system, we investigated if RNA interference (RNAi)-mediated gene silencing can be employed in order to overcome the apoptosis resistance of cancer cells. We found that both vector-borne and synthetic small interfering (si)RNAs, specifically directed against the antiapoptotic HPV E6 oncogene, restored dormant tumour suppressor pathways in HPV-positive cancer cells that are otherwise inactive in the presence of E6. This ultimately resulted in massive apoptotic cell death, selectively in HPV-positive tumour cells. These findings show that RNAi provides a powerful molecular strategy to inactivate intracellular E6 function efficiently. Moreover, they define E6 as a most promising therapeutic target to eliminate HPV-positive tumour cells specifically by RNAi. Thus, by sequence-specific targeting of antiapoptotic genes, siRNAs may be developed into novel therapeutics that can efficiently correct the apoptosis deficiency of cancer cells.
Introduction
Certain types of human papillomaviruses (HPVs) are closely associated with the development of a variety of different tumour entities in humans (zur Hausen, 2002) , including cervical carcinoma, which represents the second most common cancer in females worldwide (Parkin et al., 2001) . The transforming activity of tumour-associated high-risk HPV types, such as HPV16 and HPV18, is dependent on the functions of the viral E6 and E7 oncogenes and continuous E6/E7 expression is required for the maintenance of the transformed phenotype of HPV-positive cervical cancer cells (von Knebel Doeberitz et al., 1988) . The E6 and E7 proteins appear to cooperate functionally during cellular transformation. According to one model, E7 acts as a mitotic mutator and growth-stimulatory factor that interferes with cellular senescence and proper differentiation, whereas E6 counteracts the apoptotic response of HPV-positive cells towards the abnormal growth stimulus exerted by E7, ultimately resulting in deregulated growth of genetically unstable cells (HoppeSeyler and Butz, 1999; Mantovani and Banks, 2001; Mu¨nger et al., 2001) . Despite the worldwide biomedical significance of HPV-associated cancers and intense research efforts, specific clinical treatment regimens are still not available, and thus, the development of novel therapeutic strategies is urgently required.
RNA interference (RNAi) has been originally discovered as a mechanism of post-transcriptional gene silencing in plants and animals (Fire et al., 1998) . Importantly, RNAi can be achieved in mammalian cells following transfection of synthetic 21-and 22-nucleotide (nt) small interfering (si)RNAs with overhanging 3 0 ends (Elbashir et al., 2001) , indicating that RNAi may serve as a powerful technology to block the expression of target genes specifically. As such, the use of siRNAs with the purpose of inhibiting the expression of defined target genes has obvious therapeutic potential. For instance, it was recently reported that HIV-1 replication can be inhibited by siRNAs targeting various regions of the viral genome (Jaque et al., 2002; Lee et al., 2002; Novina et al., 2002) and that siRNAs specifically targeting mutant K-RAS reversed the oncogenic phenotype of cancer cells (Brummelkamp et al., 2002a) . To circumvent both the transient nature of transfected siRNAs and the requirement for their chemical synthesis, vector systems for the expression of siRNAs have been developed (summarized in Paddison and Hannon, 2002) . In such vectors, oligonucleotide sequences homologous to the target gene of interest are expressed from Pol III promoters, eventually resulting in biologically active siRNAs.
In a recent study, the siRNA technology was applied in order to inhibit HPV oncogene expression (Jiang and Milner, 2002) . The authors reported that the inhibition of the E6 gene did not increase the apoptotic rate of HPV-positive cancer cells, but rather proposed that the E7 gene is the therapeutic target of choice for the elimination of HPV-positive cancer cells. The results were in clear contrast with our findings that the specific targeting of the E6 protein by peptide aptamers resulted in the apoptotic elimination of HPV-positive cancer cells (Butz et al., 2000) . We show here that siRNAs, which specifically blocked E6 expression, led to the induction of cellular pathways that are otherwise inactive in the presence of the E6 protein. This ultimately led to a dramatic induction of apoptosis, which was observed selectively in HPV-transformed cells. We conclude that (i) siRNAs directed against E6 provide excellent molecular tools to inhibit intracellular E6 activities specifically and efficiently, (ii) E6 function is absolutely required for the protection of HPV-positive tumour cells from apoptosis, and thus, (iii) in contrast to the findings of Jiang and Milner, the E6 gene represents a most promising therapeutic target for the treatment of HPVpositive tumours and dysplasias.
Results
HPV18-positive cancer cell lines typically contain integrated HPV genomes, which exhibit a similar transcription pattern (Schneider-Gaedicke and Schwarz, 1986) . In general, three classes of transcripts are generated with the potential to encode the viral E6 and E7 proteins (Figure 1a ). The E6 protein is generated from class 1 transcripts, which are the only transcripts that contain the complete E6 open reading frame (ORF). Class 2 and class 3 transcripts are spliced within the E6 ORF and cannot encode a full-length E6 protein, but possibly code for a putative E6* protein (SchneiderGaedicke and Schwarz, 1986) . In order to block E6 expression selectively by RNAi, a 19-nt sequence within the HPV18 E6 intron, which is present only in class 1 transcripts, was chosen as the siRNA target ( Figure 1a ). This 19-nt target sequence, separated by a 9-nt spacer from its reverse complement sequence, was introduced into the siRNA generating pSUPER vector system (Brummelkamp et al., 2002b) , yielding pSUPER-18E6. The predicted secondary structure of the pSUPER-18E6 transcript is indicated in Figure 1b .
HPV18-positive HeLa cells were chosen for RNA and protein studies, since they reproducibly exhibited high DNA transfection efficiencies of more than 85% following calcium phosphate co-precipitation (Chen and Okayama, 1987) , thereby allowing expression studies in transient transfections. In order to investigate the effects of pSUPER-18E6 on HPV transcription and to allow a differentiation between different transcript classes, relative quantitative RT-PCR analyses were performed, using 18S rRNA as an internal control (488 bp fragment in Figure 1c ). Amplification with a primer pair that flanks the splice acceptor/splice donor site in E6 (PCR I) led to two products: a shorter product with the expected length of 204 bp, representing the spliced class 2 and 3 transcripts, and a longer product with the expected length of 387 bp, representing unspliced class 1 transcripts, which encode E6 (Figure 1c ). The transfection of pSUPER-18E6 strongly reduced the levels of class 1 transcripts, when compared to control cells transfected with control vector pSU-PER-Luc, but did not significantly affect class 2 and 3 transcript levels. In some experiments, the longer PCR Figure 1c ) that may possibly be due to single-stranded products produced during the PCR reaction. In order to further corroborate that pSUPER-18E6 induces reduction of class 1 transcripts, we therefore performed a PCR reaction in which one primer binds within the HPV18 E6 intron and the second primer binds 3 0 to the splice acceptor site (PCR II). As expected, this led to the selective amplification of class 1 transcripts, resulting in a PCR product of 243 bp (Figure 1c) . Again, pSUPER-18E6 induced a strong reduction of class 1 transcripts (more than 75%, as estimated from densitometric scanning). Thus, pSUPER-18E6 efficiently reduced the amounts of E6-coding class 1 transcripts without significantly affecting class 2 and 3 transcripts.
The effect of pSUPER-18E6 on E6 gene activities was assessed functionally, since there are no antibodies available that reliably detect the presumably very low amounts of endogenous E6 protein in HPV-positive cancer cells. The full-length E6 proteins, but not the putative truncated E6* forms (see above), of high-risk HPVs induce the proteolytic degradation of p53 (Scheffner et al., 1990) . In line with a specific targeting of E6, p53 protein levels increased in HeLa cells following transfection with pSUPER-18E6, when compared to cells transfected with pSUPER or with pSUPER-Luc ( Figure 2 ). In contrast, transfection of pSUPER-p53 strongly reduced p53 protein levels in HeLa cells, as expected (Brummelkamp et al., 2002b) .
The increase in p53 protein levels, in the presence of pSUPER-18E6, was accompanied by a strong increase of p21 gene expression (Figure 2 ), which is a transcriptional target for p53 (El-Deiry et al., 1993) . This indicates that p53 not only accumulates but that it is also functionally active upon knockdown of E6 expression. Theoretically, increase of p21 activities should result in reduced phosphorylation of the retinoblastoma tumour suppressor protein, pRb, due to an increased functional inhibition of cyclin-dependent kinases (Mittnacht, 1998) . Indeed, analysis of the pRb protein showed a reduction of hyperphosphorylated forms and an increase in hypophosphorylated pRb in the presence of pSUPER-18E6 (Figure 2 ). Moreover, in support of the selective targeting of E6, we found that pSUPER-18E6 did not affect the steady-state levels of the HPV18 E7 protein (Figure 2 ). We conclude that pSUPER-18E6 can specifically inhibit E6 activities in HPV-positive cancer cells, without affecting E7 expression, thereby leading to the activation of cellular pathways that are blocked by the E6 oncoprotein in untreated cells.
To support further the notion that pSUPER-18E6 restores dormant p53 activities by interfering with E6 expression, luciferase reporter assays were performed. Transfection of HeLa cells with pSUPER-18E6 resulted in the activation of reporter plasmids under the transcriptional control of the p21 promoter or of a synthetic p53-consensus recognition site upstream of a minimal promoter, but not of the human b-actin promoter, serving as a negative control (Figure 3a) . Importantly, ectopic expression of the HPV16 E6 gene, which similar to HPV18 E6 induces p53 degradation but does not bear the siRNA target sequence, counteracted the effects of pSUPER-18E6 in HeLa cells (Figure 3b ). In contrast, ectopic expression of the HPV6 E6 gene, which does not induce p53 degradation, did not reverse the effects of pSUPER-18E6 (Figure 3b ). Thus, siRNAmediated inhibition of HPV18 E6 can be specifically rescued by ectopic expression of a functional homologous E6 protein derived from another oncogenic HPV type, further demonstrating that the observed cellular effects are due to the specific targeting of E6.
In order to study the cellular consequences of siRNAmediated targeting of E6, we performed colony formation assays. To this end, cells were transfected with either pSUPER-18E6 or control vector pSUPER-Luc, together with pSV2Neo (Southern and Berg, 1982) to allow for the selection of transfected cells by neomycin resistance. As shown in Figure 4a , pSUPER-18E6 had a dramatic effect on HPV18-positive HeLa cells, virtually completely abolishing their colony formation capacity. This effect was specific for HPV-positive cells, since the growth of HPV-negative cells, such as H1299 (Figure 4a ) or MeWo cells (not shown), was not affected by pSUPER-18E6.
In order to obtain an insight into the molecular mechanisms that block the growth of pSUPER-18E6-transfected cells in colony formation assays, cells were examined for signs of apoptosis by TdT-mediated dUTP biotin nick end labelling (TUNEL). As shown in Figure 4b , pSUPER-18E6-transfected HeLa cells exhibited a massive induction of apoptosis when compared to control-transfected cells, as visualized by a strong siRNA against HPV E6 K Butz et al reduction in cell numbers, increased chromatin condensation, and a positive TUNEL assay. We conclude that siRNA directed against HPV18 E6 specifically kills HPV18-positive cancer cells with high efficiency, through the induction of apoptotic cell death. In contrast to our findings, a recent study has reported that synthetic siRNA directed against intron sequences of the HPV16 E6 gene induced only a marginal G1 arrest and no signs of apoptosis in HPVpositive tumour cell lines (Jiang and Milner, 2002) . In order to investigate whether these contrasting results may be due to the different virus types tested or to the different origins of the employed siRNAs (vectorborne versus chemically synthesized), we also analysed the effects of synthetic siRNAs targeting the intron sequences within the HPV16 and HPV18 E6 genes, respectively ( Figure 5 ). In agreement with the results obtained with pSUPER-18E6, transfection of synthetic siRNAs targeting HPV16 E6 or HPV18 E6 resulted in an increase of p53 protein levels and a strong induction of apoptosis in HPV16-or HPV18-positive tumour cells, respectively ( Figure 5 ). In contrast, HPV-negative control cells, such as MCF-7 breast cancer (wild-type p53) or H1299 lung cancer cells (p53 null) were not affected ( Figure 5 ). Thus, both synthetic and vectorborne siRNAs that target the HPV16 and HPV18 E6 In support of the concept that HPV-positive cancer cells contain dormant tumour suppressor pathways, which can be reactivated (Butz et al., 1995 (Butz et al., , 2000 Goodwin and DiMaio, 2000; Wells et al., 2000) , siRNA targeting of HPV18 E6 resulted in the restoration of p53-associated pathways in HeLa cervical carcinoma cells. This included an increase in p53 protein levels, the transcriptional stimulation of p53-responsive promoters and, accordingly, an increase in p21 protein concentrations, as well as an increase in hypophosphorylated pRb. These effects were due to selective targeting of HPV18 E6, since we did not observe alterations in viral E7 protein expression and since ectopic expression of HPV16 E6, a functional homologue of HPV18 E6, specifically counteracted the siRNA effects. Eventually, upregulation of p53, following siRNA targeting of E6, was associated with a dramatic induction of apoptosis, thereby supporting the notion that E6 acts as an antiapoptotic factor by interfering with the function of p53 (Pan and Griep, 1994) , although additional p53-independent antiapoptotic activities of E6 may also be affected Banks, 1998, 1999) . In further support of the specificity of the experimental approach, apoptosis was only observed in HPV-positive cancer cells, whereas the growth of HPV-negative cells remained unaffected.
Our results are in contrast to a recent study reporting that the targeting of HPV16 E6 by synthetic siRNAs resulted in only a very modest growth inhibition of HPV16-positive cancer cells, with no signs of significant cell death (Jiang and Milner, 2002) . These deviant results may be explained by the fact that the efficiency of siRNAs can greatly depend on the target sequence (Brummelkamp et al., 2002b; Elbashir et al., 2002) 
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Figure 5 Synthetic siRNAs against E6 induce p53 accumulation and apoptosis in HPV-positive cancer cell lines. siRNAs specific for HPV-18 E6 (HeLa, H1299, MCF-7) or HPV-16 E6 (SiHa, H1299, MCF-7) were transfected into the cell lines indicated. As control, cells were transfected with the sense strand of the respective siRNA. As a measure of transfection efficiency, cells were incubated with FITC-dextran in the presence (FITC þ oligof.) or in the absence (FITCÀoligof.) of Oligofectamine, as indicated. Levels of p53 and induction of apoptosis, respectively, were determined 24 h (d1) and 96 h (d4) after transfection by fluorescence analysis. In addition, cells were visualized by phase-contrast microscopy (PC) and nuclei by DAPI siRNA against HPV E6 K Butz et al discrepant results are due to differences between synthetic and vector-borne siRNAs or to different virus types investigated can be excluded, since we also observed a dramatic induction of apoptosis following treatment of both HPV16-and HPV18-positive cancer cells with synthetic siRNAs against E6 ( Figure 5 ). In addition, Jiang and Milner reported a specific activation of E7-associated pathways and a limited induction of apoptosis through an siRNA directed against the E7 portion of the viral transcripts, postulating that E7 represents the therapeutic target of choice. Yet, in view of the transcription patterns of oncogenic HPVs (Schneider-Gaedicke and Schwarz, 1986; Smotkin et al., 1989 ; see also Figure 1a ), it is not apparent how a selective inhibition of E7 could be achieved by such an approach. Several antisense-based strategies have previously been used in order to target HPV transcription. However, the efficacy of such approaches was limited in most studies and, in contrast to the massive induction of apoptosis following siRNA targeting of E6, usually some degree of growth inhibition was reported, rather than induction of apoptosis (Venturini et al., 1999 , and references therein). These differences may be related to the fact that HPV E6/E7 transcripts exhibit low accessibility for antisense nucleic acids (Venturini et al., 1999) and RNAi may provide a more efficient way of targeting the viral transcripts for inactivation. In addition, it should be noted that antisense constructs have mostly been designed in a way that they inhibit the expression of both E6 and E7, thereby possibly allowing escape of the treated cells from a proapoptotic influence of E7. In contrast, the siRNA approach followed in this study specifically inhibited E6 function, but did not affect E7 expression, and thereby should maintain the putative proapoptotic activity of E7. The siRNA technology may also be helpful to elucidate this issue in future studies, if it is possible to create siRNAs that specifically and efficiently target E7 for inactivation, without affecting E6 expression.
Agents inducing apoptosis, as observed in this study, should bear a great therapeutic advantage over agents inducing reversible growth inhibition, since the former may not require continuous application. Indeed, it becomes increasingly clear that antiapoptotic factors play a decisive role for malignant cell growth and the targeted inhibition of these factors is considered to be one of the most promising approaches for the development of novel anticancer strategies (Nicholson, 2000; Reed, 2001; Igney and Krammer, 2002) . For instance, a series of different tumour entities exhibit aberrant expression of antiapoptotic factors belonging to the inhibitors of apoptosis protein family (Salvesen and Duckett, 2002) and their specific inhibition by small peptides has been shown to sensitize tumour cells to apoptosis, in cooperation with other proapoptotic agents (Fulda et al., 2002) . Interestingly, the E6-targeting siRNAs identified here are by themselves sufficient for apoptosis induction in HPVpositive cancer cells.
It will be one of the major future tasks for molecular medicine to translate the great therapeutic potential of RNAi into clinical application (Agami, 2002; Paddison and Hannon, 2002) . The development of gene therapy vectors expressing siRNAs should be technically feasible, but their use will have to meet the general challenges associated with gene therapy, such as the necessity for efficient gene delivery into the correct cells and the circumvention of interfering systemic immune responses. Yet, for the delivery of siRNA-encoding vectors into lesions of the skin and mucosa, such as HPV-associated lesions, alternative delivery routes could be envisioned. Translocating peptides have been developed, which allow the efficient introduction of plasmid DNA into living cells (Morris et al., 2000; Rittner et al., 2002) ; other peptides have been shown to penetrate into all cell layers of intact human skin (Rothbard et al., 2000) . Further development of these techniques may provide an interesting route for the topical application of siRNA-coding vectors, which, in the case of HPV-associated lesions, should yield specificity of action by targeting viral transcripts that are present only in infected cells.
Materials and methods

Plasmids and synthetic siRNAs
Vector pSUPER generates biologically active siRNAs from the Pol III H1-RNA gene promoter (Brummelkamp et al., 2002b) . A synthetic double-stranded oligonucleotide (5 0 -CTAACACTGGGTTATACAAttcaagagaTTGTATAACCCAG-TGTTAG-3 0 ) was introduced into pSUPER, resulting in pSUPER-18E6. Oligonucleotide sequences correspond to a 19-nt sequence from HPV18 E6 (nucleotides 385-403, numbering according to (Cole and Danos, 1987) ) which are separated by a 9-nt linker (lower case letters) from the reverse complement of the same 19-nt sequence. To generate control vector pSUPER-Luc, the double-stranded synthetic oligonucleotide 5 0 -CATCACGTACGCGGAATACttcaagagaGTATTCCGC-GTACGTGATG-3 0 (containing 19-nt derived from the Photinus pyralis (variant GL2) luciferase gene, separated by a 9-nt linker from its reverse complement) was introduced into pSUPER. Vector pSUPER-p53 targets p53 transcripts and has been described before (Brummelkamp et al., 2002b) .
Synthetic siRNAs against mRNAs encoding HPV-16 E6 and HPV-18 E6, respectively, were obtained from Dharmacon Research (Lafayette, USA). The respective target sequence was for HPV-16 E6 5 0 -UACAACAAACCGUUGUGUG (nucleotides 377-395), and for HPV-18 E6 5 0 -CUAACUAACA-CUGGGUUAU (nucleotides 381-399).
For reporter gene analyses, the P. pyralis luciferase gene was under transcriptional control of a p53-consensus recognition site upstream of a minimal promoter in p53CONLuc (Funk et al., 1992) , of the p21 promoter in p21Luc, and of the human b-actin promoter in pAcLuc. Plasmids p6E6 and p16E6 express the complete HPV6 and HPV16 E6 genes, respectively, from the Harvey murine sarcoma virus long terminal repeat; pLTR is the corresponding expression vector devoid of E6 inserts (Sedman et al., 1991 (Chen and Okayama, 1987) . Synthetic siRNAs (60 pmol per well of a 24-well plate) were transfected by Oligofectamine according to the manufacturer's instructions (Invitrogen, Karlsruhe, Germany).
For luciferase assays, cells were plated on 6 cm Petri dishes and transfected with 2 mg of the respective luciferase reporter plasmids, 4 mg of either pSUPER or pSUPER-18E6, and 0.5 mg of the internal standard CMV-Gal, expressing the Escherichia coli b-galactosidase gene under control of the human cytomegalovirus promoter, to correct for possible variations in transfection efficiencies (Butz et al., 1995) . In order to analyse the effects of ectopically expressed E6, 1.5 mg p53CONLuc, 3 mg of either pSUPER or pSUPER-18E6, 0.5 mg of CMV-Gal, and 1.5 mg of either p6E6, p16E6, or pLTR were cotransfected, as detailed in the text. Cells were harvested 48 h after transfection, processed as described (Butz et al., 1995) , and luciferase activities were quantitated using a Luci 1 microplate luminometer (Anthos, Krefeld, Germany).
Protein and RNA analyses
Protein extracts were prepared 48 h after transfection, essentially as previously described (Butz et al., 1995) . For Western blot analyses, approximately 30 mg of protein was separated by 10% SDS-PAGE (except for pRb analyses, where 100 mg of protein were separated by 7.5% SDS-PAGE) transferred to a Immobilon-P membrane (Millipore, Eschborn, Germany) and analysed by enhanced chemiluminescence (Amersham Biosciences, Freiburg, Germany) using anti-p21 antibody OP-64 (Calbiochem, Schwalbach, Germany), anti-p53 antibody DO-1 (Pharmingen, San Diego, USA), anti-pRb antibody G3-245 (Pharmingen), anti-HPV18 E7 antibody 18E7C (Butz et al., 1998) , and antitubulin antibody Ab-1 (Oncogene, Boston, USA).
Relative quantitative RT-PCR analysis was performed using the QuantumRNAt 18S Internal Standards kit (Ambion, Austin, USA), following the manufacturer's instructions. Cells were transfected with either pSUPER-18E6 or pSUPERLuc, together with pSV2Neo (Southern and Berg, 1982) and treated for 72 h with 1 mg/ml Geneticin (Invitrogen) to allow for the selection of transfected cells by neomycin resistance. Subsequently, RNA was isolated (Chomczynski and Sacchi, 1987) and RT-PCR was performed by using random decamers. For the amplification of all E6/E7 transcript classes, primers 18E6for1 (5 0 -GCGACCCTACAAGCTACCTG-3 0 , HPV18 nucleotide positions 131-150) and 18E6rev1 (5 0 -GCACTGGCCTCTATAGTGCC-3 0 , HPV18 nucleotide positions 518-499) were utilized, which flank the splice donor/ splice acceptor site within the E6 gene. In order to amplify class 1 transcripts specifically, PCR was performed employing primer 18E6for2 (5 0 -AGACAGTATACCCCATGCTGC-3 0 , HPV18 nucleotide positions 275-295), which locates to the E6 intron, and primer 18E6rev1. In each amplification reaction, the 18S rRNA PCR primer/competimer pairs provided by the manufacturer were included into the reaction as internal control. Following separation on a 3% nondenaturing agarose gel, the amplification products were transferred to a Hybond-N þ nylon transfer membrane (Amersham Biosciences) and detected with radiolabelled probes for 18S rRNA and HPV18 E6/E7 (nucleotides 416-611). Individual amplification products were quantitated in the linear range of the PCR by densitometric scanning (Storm 860 and Storm Scanner Control Version 5.0, Amersham Biosciences), and determined relative to the 18S rRNA amplification product, which served as an internal standard.
Colony formation assays, detection of apoptosis
Cells were transfected with either pSUPER-18E6 or pSUPERLuc, together with pSV2Neo (Southern and Berg, 1982) to allow for the selection of transfected cells by neomycin resistance. Colonies were fixed with formaldehyde and stained with crystal violet. For apoptosis detection, cells were split after transfection and grown on coverslips in the presence of 1 mg/ml Geneticin for 3 days. TdT-mediated dUTP biotin nick end labelling (TUNEL) analyses were performed, using the in situ cell death detection kit (Roche Molecular Biochemicals, Mannheim, Germany), as previously described (Butz et al., 2000) . In experiments with synthetic siRNAs, TUNEL analysis was performed 24-96 h after transfection. In addition, p53 was detected by the rabbit polyclonal antibody FL393 (Santa Cruz, Heidelberg, Germany) by immunofluorescence. Total DNA was stained with 4 0 ,6-diamidino-2-phenylindole (DAPI, Roche Molecular Biochemicals). Apoptotic strand breaks and total DNA were visualized by transmission epifluorescence microscopy.
